PolyBio Research Foundation

PolyBio Research Foundation A 501(c)3 transforming the study of infection-associated chronic disease

At PolyBio, we believe that chronic inflammatory diseases are not mysterious or hopeless. The opposite is true: we can use new tools to study pathogen activity, environmental exposures, microbiome imbalances, neuroinflammation, gene changes, and other issues in patients with such conditions. PolyBio brings together some of the brightest minds in science to research these topics in a proactive and

open-minded fashion. PolyBio was founded by three scientists with complementary expertise (neuroscience, microbiology & genetics). We conceptualize research projects that identify root cause drivers of these conditions, and build teams to make the projects a reality.

06/16/2026

“What we’re finding across the genome are specific variants that are very much enriched, and have highly likely loss-of-function in these patients with [severe] Long COVID,” said Dr. Petter Brodin on his team’s PolyBio-supported genome study of Long COVID patients.

“The challenge that we’re currently facing is to take these variants into the relevant cell type where we think they actually exert their function,” such as human organoid models of the intestinal epithelium, allowing the team to observe how these variants impact tissue-based disease.

This PolyBio-supported project is determining underlying genetic causes, and other modifying factors like s*x hormones and interferon responses, impacting restrained T cell responses to SARS-CoV-2 & viral persistence in LongCOVID. The study is being performed in a group of 500< severe and uniquely well characterized Long COVID patients, with signs of organ dysfunction or disease after mild/moderate COVID-19.

The team is performing whole genome sequencing and variant analyses in relation to over 3000 whole genomes obtained from patients with variable presentations following SARS-CoV-2 infection within the global COVID Human Genetic Effort Consortium. The genetic analyses are being combined with other forms of research including immune cell profiling and experiments in lymphoid organoid cultures.

Read the full study summary: https://polybio.org/projects/genetic-variants-restrained-antiviral-immunity-in-severe-longcovid/

Watch Dr. Brodin’s full presentation from PolyBio’s Spring 2026 symposium: https://youtu.be/tD5gWVEjudQ?t=1881&si=pcCfgIbiF0JXmh1M

06/09/2026

Dr. Tim Henrich presented new findings surrounding long term persistence of SARS-CoV-2 proteins & RNA in Long COVID gut tissue at PolyBio’s recent Spring symposium. “We actually see [gut viral persistence] in both areas, the epithelium—which turns over every several days to week—to the lamina propria where you have long-lived myeloid immune cells… suggesting there may even be replication in some individuals,” said Henrich.

Using a highly sensitive method of detecting viral RNA, “around 20-25% of the time, we see detection… all the way up until 3-4 years after initial infection” in Long COVID patients.

Dr. Henrich’s findings are part of the PolyBio-supported PASC tissue program within the LIINC collaborative. The program is the first in the world to comprehensively sample multiple tissues including gut, lymph node, cerebrospinal fluid, and bone marrow to test the hypothesis that tissue-based viral persistence drives Long COVID and can be altered via interventions targeting viral reservoirs.

The Program is also leveraging Long COVID clinical trials targeting mechanisms of viral persistence (e.g. the Aerium monoclonal antibody trial and the Shionogi antiviral trial) to support deep assessment of the impact of such interventions on measures of viral persistence.

Read the full project summary: https://polybio.org/projects/liinc-pasc-tissue-program-a-multimodal-assessment-of-the-tissue-based-virologic-drivers-of-long-covid/

Watch Dr. Henrich’s full presentation from PolyBio’s Spring 2026 symposium here: https://youtu.be/tD5gWVEjudQ?t=13416&si=vjWUbf1X8VFfX4s5

Read the full technical summary from Dr. Henrich’s symposium presentation here: https://2026-spring-symposium-polybio.netlify.app/ -tissue

06/03/2026

Said Dr. Mark Painter in a recent episode of PolyBio’s Lab Visits: “What we’re seeing in a third of people with Long COVID, maybe more, is evidence that T cells recognizing either SARS-CoV-2—or in some different people, herpesviruses—are persistently activated. Which is suggestive that those viruses are present somewhere in the body.”

Dr. Painter and his colleagues at the Wherry Lab at University of Pennsylvania are a part of PolyBio’s VIPER diagnostics validation network, which will help evaluate their CD8+ T cell biosensor method for the detection of viral pathogens in a Long COVID patient cohort.

Full interview with Dr. Painter: https://youtu.be/H_3dKzNw3Wk?si=OCd94C_xvYPW4oeg

Learn more about the VIPER diagnostics program: https://polybio.org/viper/

06/01/2026

Written summaries of PolyBio’s Spring symposium presentations are available now! Check out shortened, simplified summaries, or full technical explanations of your favourite research projects.

https://2026-spring-symposium-polybio.netlify.app/

BREAKING: Funding from Vitalik Buterin’s Balvi Fund Expands Long COVID Low-Dose Rapamycin Trial💊 See participant require...
05/29/2026

BREAKING: Funding from Vitalik Buterin’s Balvi Fund Expands Long COVID Low-Dose Rapamycin Trial

💊 See participant requirements below—we are actively recruiting Long COVID patients for this trial.

Medford, MA , May 29, 2026 — PolyBio Research Foundation today announced new funding from the Balvi Fund to accelerate a clinical trial investigating low-dose rapamycin as a potential treatment for Long COVID. The funding will support an open-label extension phase that will allow all participants – including those initially randomized to placebo – to receive low-dose rapamycin during a defined follow-up period, an approach expected to improve willingness to enroll while preserving the rigor of the randomized controlled phase of the trial. The support will also allow study coordinators to conduct home visits for certain participants to collect blood samples, helping expand access for individuals who are too ill or geographically constrained to consistently travel to study sites.

The Balvi Fund is a direct giving and scientific investment fund established by Vitalik Buterin to support high-impact projects in biosecurity, pandemic prevention, and public health.

“Vitalik and the Balvi Fund have been incredible supporters of both PolyBio and the broader Long COVID research space over the years,” said Dr. Amy Proal, President of PolyBio Research Foundation. “This new grant continues that commitment in a meaningful way by helping us run a stronger and more accessible clinical trial while generating the kind of mechanistic immune data needed to move the field toward targeted treatments.”

The trial is based on a mechanistic hypothesis: that low-dose rapamycin may recalibrate aspects of the immune response in a way that improves the body’s ability to suppress chronic viral activity. This approach draws on evidence from the healthspan and aging field, where analogs of rapamycin have been shown to enhance antiviral interferon signaling, modulate T cell exhaustion, and improve antibody responses to vaccination.

To directly investigate these effects in Long COVID, the lab of Akiko Iwasaki at Yale University is conducting deep immune profiling on participant blood samples collected before and after treatment. These analyses are designed to determine whether rapamycin increases interferon signaling, reverses features of T cell exhaustion, and strengthens antiviral immune responses—data that could help clarify how the drug should be deployed in Long COVID and related chronic conditions.

By adding an open-label extension, the enhanced trial is positioned to generate high-resolution data on how rapamycin shapes immune function in Long COVID. These findings will help determine whether—and in which patient subsets—the drug may have therapeutic value, advancing the field toward more precise, mechanism-based treatment strategies.

🏥 The Cohen Center for Recovery from Complex Chronic Illness is actively recruiting for this Long COVID trial.

Interested in participating? Participants should:

-be 18 years or older
-have a confirmed Long COVID diagnosis from a physician
-prepare to travel to the CoRE clinic in NYC for clinical visits (if possible).

Email [email protected] to apply.

Read more: https://polybio.org/funding-from-vitalik-buterins-balvi-fund-expands-long-covid-rapamycin-trial/

Breaking: PolyBio-Supported Study Identifies Association between HHV-6 Reactivation & Long COVID Symptom SeverityA colla...
05/23/2026

Breaking: PolyBio-Supported Study Identifies Association between HHV-6 Reactivation & Long COVID Symptom Severity

A collaborative study between the laboratory of Akiko Iwasaki at Yale University and the Cohen Center for Recovery from Complex Chronic Illness at the Icahn School of Medicine at Mount Sinai has identified a potential link between reactivation of the herpesvirus HHV-6 and Long COVID symptom severity. The work adds to growing evidence that chronic viral reactivation may contribute to the biological mechanisms underlying Long COVID.

The study examined whether reactivation of human herpesviruses could be associated with persistent symptoms following SARS-CoV-2 infection. Prior research has linked herpesvirus reactivation—particularly Epstein-Barr virus (EBV)—to more severe acute COVID-19 and increased risk of developing Long COVID. However, less is known about how active herpesvirus shedding relates to ongoing symptom burden over time.

To investigate this question, the research team enrolled 45 participants with Long COVID and 45 age- and s*x-matched controls. Participants completed detailed symptom surveys and provided saliva samples at multiple timepoints across two consecutive days. The team measured salivary cortisol, testosterone, and estradiol levels while simultaneously testing saliva for DNA from multiple herpesviruses—including EBV, HSV-1/2, HCMV, and HHV-6 A/B—alongside SARS-CoV-2 RNA.

The researchers found that detection of EBV and HHV-6 DNA was highest early in the morning. While overall herpesvirus shedding and hormone levels did not significantly differ between Long COVID participants and controls, one signal stood out: higher levels of salivary HHV-6 DNA were associated with greater Long COVID symptom severity, including stronger associations with anxiety, depression, and overall functional impairment.

The findings suggest that HHV-6 reactivation may contribute to chronic disease processes in at least a subset of Long COVID patients. The researchers note that while salivary EBV shedding was not associated with Long COVID in this cohort, EBV could still play a role earlier in disease progression or within tissues not sampled in the study.

The work also raises important translational questions. If future studies replicate the findings, HHV-6 could become a target for biomarker-guided clinical trials and therapeutic intervention strategies. Researchers suggest that salivary virome profiling may eventually help identify biologically distinct patient subsets who could benefit from tailored antiviral or immunomodulatory therapies.

Read more: https://polybio.org/polybio-supported-study-identifies-association-between-hhv-6-reactivation-and-long-covid-severity/

Breaking: PolyBio Launches Commercialization Advisory Network to Accelerate Long COVID Diagnostics and Treatmentshttps:/...
05/21/2026

Breaking: PolyBio Launches Commercialization Advisory Network to Accelerate Long COVID Diagnostics and Treatments

https://polybio.org/polybio-launches-commercialization-advisory-network-to-accelerate-long-covid-diagnostics-and-treatments/

PolyBio Research Foundation today announced the formal launch of its Commercialization Advisory Network, a new initiative designed to accelerate the translation of Long COVID and related chronic disease discoveries into clinical diagnostics and targeted treatments.

The Network held its inaugural meeting on Friday, May 15 at the Harvard Innovation Labs in Boston, bringing together leaders across diagnostics, biotechnology, healthcare investment, reimbursement strategy, and translational medicine.

The Network will help guide the commercialization and deployment of next-generation diagnostic platforms capable of identifying key biological drivers of Long COVID, including persistent viral reservoirs, pathogen reactivation, and immune dysfunction.

“The bottleneck in Long COVID is no longer simply discovery,” said Caroline Rossiter, PolyBio’s Director of Operations and Innovation. “Academic researchers are increasingly identifying clear biological abnormalities in patients. The challenge now is to help them translate those findings into validated diagnostics, targeted clinical trials, and treatments that can actually reach patients. The Commercialization Advisory Network was built specifically to help solve that problem.”

A central focus of the initiative is VIPER, PolyBio’s large-scale Long COVID diagnostics validation program. Modeled in part after successful HIV assay validation efforts, VIPER is designed to rigorously compare and validate diagnostic technologies across laboratories and patient cohorts, with the goal of identifying the assays best positioned for clinical deployment and use in mechanistic clinical trials.

Members of the Network bring expertise spanning the full translation process: diagnostic product development, liquid biopsy technologies, reimbursement and insurance strategy, venture creation, companion diagnostics, and biotechnology commercialization. The group includes leaders from StudioDx, AnywhereDx, Exosome Diagnostics, Santé Ventures, Invivyd, Enanta Pharmaceuticals, American Cancer Society BrightEdge, and The Michael J. Fox Foundation for Parkinson’s Research.

The first meeting focused on strategies to accelerate the validation, commercialization, and clinical adoption of Long COVID diagnostics being advanced through the Long COVID Cure Initiative. Discussions included regulatory strategy, payer adoption, clinical trial integration, commercialization pathways for academic technologies, and approaches to building companion diagnostics that can help match patients with targeted therapies.

While initially focused on Long COVID through PolyBio’s Long COVID Cure Initiative (LCCI), the Network will also help guide translational efforts in related infection-associated chronic illnesses including chronic Lyme disease, Alzheimer’s, and aspects of human aging increasingly linked to chronic infection and immune dysfunction.

MEET SELECT MEMBERS OF THE COMMERCIALIZATION NETWORK

DEVIN CAMPBELL, Prodct

Devin is the Founder of Prodct, where he works with scientific and technology-driven organizations to build products that translate complex ideas into scalable real-world tools.

HANNAH MAMUSZKA, Alva10

Hannah is the Founder and Managing Partner of Alva10, a healthcare investment firm focused on helping diagnostic companies create strategies for insurance coverage.

FARNAZ BAKHSHI, ACS Brightdge

Farnaz is Director of Innovation at ACS BrightEdge, the American Cancer Society’s mission-driven venture capital and innovation arm, where she focuses on advancing high-impact healthcare technologies from early discovery to commercialization.

TARA KIEFFER, PhD, Enanta Pharmaceuticals

Tara is Chief Product Strategy Officer at Enanta Pharmaceuticals, where she focuses on advancing innovative therapeutic platforms for complex diseases.

OMAR KHALIL, Santé Ventures

Omar is a Managing Director at Santé Ventures, where he focuses on investing in and scaling innovative healthcare and life sciences companies. He has experience in venture capital, company building, and commercialization strategy.

To meet the whole Commercialization Advisory Network, go to: https://polybio.org/polybio-commercialization-advisory-network/

Learn more about the Long COVID Cure Initiative here: https://polybio.org/lcci/

05/20/2026

One of PolyBio’s key goals at this Spring symposium on Friday, May 22: defining neuroimmune mechanisms of disease in infection-associated chronic illness. This Friday, you’ll hear our research collaborators discuss projects from a novel retinal biomarker for cognitive dysfunction, to a whole-body T cell activation study using PET imaging.

Register now for PolyBio’s scientific symposium (Friday, May 22 11 am-5 pm ET/ 3-9 pm UTC, free to attend): https://us02web.zoom.us/webinar/register/WN_VP0r-Io_SWefoRpvErHmWg #/registration

This feature on neuroimmune presentations for this Friday’s symposium only highlights some of the presenters in our exciting lineup. Check out the whole symposium schedule here: https://polybio.org/2026-spring-symposium/

05/17/2026

A major theme of PolyBio’s 2026 Spring Symposium: developing and validating Long COVID biomarkers to enable smarter clinical trials, stratified by patient subtype. Here are 6 key presenters that will discuss a promising biomarker platform on May 22. From novel platforms like extracellular vesicles & BARA, to microfluidics capture of persistent SARS-CoV-2, there’s a large body of new IACI research to explore.

Full symposium schedule & registration (Friday May 22, 11 am-5 pm ET / 3-9 pm UTC): https://polybio.org/2026-spring-symposium/

Address

Medford, MA
02155

Website

Alerts

Be the first to know and let us send you an email when PolyBio Research Foundation posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Organization

Send a message to PolyBio Research Foundation:

Shortcuts

Share

Category